LIPF | Lipase, gastric | Enzymes FDA approved drug targets Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images/45930/ihc_cell_selected_60x60.jpg) | ![](/images/45930/105130_B_8_1_rna_selected_60x60.jpg) | Tissue enriched |
LPL | Lipoprotein lipase | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images/48749/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Group enriched |
MAOA | Monoamine oxidase A | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | ![](/images/9437/30396_B_9_2_rna_selected_60x60.jpg) | Mixed |
MAOB | Monoamine oxidase B | Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | ![](/images/2328/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/2328/7274_B_9_4_rna_selected_60x60.jpg) | Mixed |
MAP1A | Microtubule-associated protein 1A | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | ![](/images/39064/1368_B10_3_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/39064/144721_B_8_4_rna_selected_60x60.jpg) | Tissue enriched |
MAP2 | Microtubule-associated protein 2 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | ![](/images/1984/5294_A_2_8_rna_selected_60x60.jpg) | Tissue enriched |
MAP2K1 | Mitogen-activated protein kinase kinase 1 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | ![](/images/26430/ihc_cell_selected_60x60.jpg) | ![](/images/3834/10782_A_2_6_rna_selected_60x60.jpg) | Expressed in all |
MAP2K2 | Mitogen-activated protein kinase kinase 2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | ![](/images/3835/11076_B_9_1_rna_selected_60x60.jpg) | Expressed in all |
MAP4 | Microtubule-associated protein 4 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/38149/84134_B_1_4_rna_selected_60x60.jpg) | Expressed in all |
MAPK1 | Mitogen-activated protein kinase 1 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/5700/20814_B_8_1_rna_selected_60x60.jpg) | Expressed in all |
MAPK11 | Mitogen-activated protein kinase 11 | Enzymes FDA approved drug targets Predicted intracellular proteins
| ![](/images/45069/ihc_selected_60x60.jpg) | ![](/images/12961/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/45069/144952_B_8_4_rna_selected_60x60.jpg) | Mixed |
MAPK3 | Mitogen-activated protein kinase 3 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | ![](/images/2683/ihc_cell_selected_60x60.jpg) | ![](/images/5700/20814_B_7_4_rna_selected_60x60.jpg) | Expressed in all |
MAPT | Microtubule-associated protein tau | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | ![](/images_static/na_center.gif) | ![](/images/151/ihc_cell_selected_60x60.jpg) | ![](/images/151/156499_A_6_1_rna_selected_60x60.jpg) | Tissue enhanced |
MET | MET proto-oncogene, receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| ![](/images/5282/ihc_selected_60x60.jpg) | | | ![](/images/5282/15801_A_8_1_rna_selected_60x60.jpg) | Expressed in all |
METAP2 | Methionyl aminopeptidase 2 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | ![](/images/19095/75457_A_1_8_selected_60x60.jpg) | ![](/images/13025/28837_B_8_1_rna_selected_60x60.jpg) | Expressed in all |
MGAM | Maltase-glucoamylase (alpha-glucosidase) | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images/2270/32_E4_2_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/2270/8419_B_8_5_rna_selected_60x60.jpg) | Group enriched |
MME | Membrane metallo-endopeptidase | Cancer-related genes Candidate cardiovascular disease genes CD markers Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/13/156692_B_8_8_rna_selected_60x60.jpg) | Tissue enhanced |
MMP10 | Matrix metallopeptidase 10 (stromelysin 2) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| ![](/images_static/rna_center.gif) | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enriched |
MMP11 | Matrix metallopeptidase 11 (stromelysin 3) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| ![](/images/2593/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2593/10111_B_8_7_rna_selected_60x60.jpg) | Group enriched |
MMP14 | Matrix metallopeptidase 14 (membrane-inserted) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| ![](/images/9918/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/9918/24804_B_9_4_rna_selected_60x60.jpg) | Expressed in all |
MMP15 | Matrix metallopeptidase 15 (membrane-inserted) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| ![](/images/40390/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/40390/92316_A_3_6_rna_selected_60x60.jpg) | Mixed |
MMP16 | Matrix metallopeptidase 16 (membrane-inserted) | Cancer-related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| ![](/images/23693/ihc_selected_60x60.jpg) | ![](/images/23693/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/23693/51538_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
MMP19 | Matrix metallopeptidase 19 | Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| ![](/images/12845/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/12845/30287_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
MMP2 | Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| ![](/images/2788/6952_B_5_3_selected_60x60.jpg) | ![](/images/1939/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/2788/6951_B_1_4_rna_selected_60x60.jpg) | Expressed in all |
MMP21 | Matrix metallopeptidase 21 | Enzymes FDA approved drug targets Predicted secreted proteins
| ![](/images/24429/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/24429/53292_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
MMP23B | Matrix metallopeptidase 23B | Enzymes FDA approved drug targets Predicted intracellular proteins
| ![](/images/2768/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2768/6683_B_8_1_rna_selected_60x60.jpg) | Mixed |
MMP24 | Matrix metallopeptidase 24 (membrane-inserted) | Enzymes FDA approved drug targets Predicted membrane proteins
| ![](/images/49280/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/49280/112178_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
MMP25 | Matrix metallopeptidase 25 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| ![](/images/25177/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/25177/79659_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
MMP27 | Matrix metallopeptidase 27 | Enzymes FDA approved drug targets Predicted secreted proteins
| ![](/images/69097/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/69097/153034_B_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
MMP3 | Matrix metallopeptidase 3 (stromelysin 1, progelatinase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| ![](/images/7875/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/7875/20325_B_8_6_rna_selected_60x60.jpg) | Group enriched |
MMP7 | Matrix metallopeptidase 7 (matrilysin, uterine) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| ![](/images/25869/ihc_selected_60x60.jpg) | ![](/images/51358/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/25869/59097_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
MMP8 | Matrix metallopeptidase 8 (neutrophil collagenase) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/22935/50810_A_2_4_rna_selected_60x60.jpg) | Tissue enriched |
MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | ![](/images/1238/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/63909/152372_A_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
MTOR | Mechanistic target of rapamycin (serine/threonine kinase) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| ![](/images/5057/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/5057/18352_B_8_1_rna_selected_60x60.jpg) | Expressed in all |
MTR | 5-methyltetrahydrofolate-homocysteine methyltransferase | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| ![](/images_static/rna_center.gif) | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Expressed in all |
MTTP | Microsomal triglyceride transfer protein | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| ![](/images/54862/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/54862/128137_B_8_2_rna_selected_60x60.jpg) | Group enriched |
MUT | Methylmalonyl CoA mutase | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | ![](/images/35971/if_selected_60x60.jpg) | ![](/images/35971/145837_A_4_7_selected_60x60.jpg) | ![](/images/35971/74640_B_8_3_rna_selected_60x60.jpg) | Expressed in all |
NFKB1 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins Transcription factors
| | | | ![](/images/4031/11359_A_8_5_rna_selected_60x60.jpg) | Expressed in all |
NNMT | Nicotinamide N-methyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| ![](/images/59180/ihc_selected_60x60.jpg) | ![](/images/59180/1184_C12_2_selected_60x60.jpg) | ![](/images/59180/ihc_cell_selected_60x60.jpg) | ![](/images/59180/132923_B_8_4_rna_selected_60x60.jpg) | Expressed in all |
NOS2 | Nitric oxide synthase 2, inducible | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| ![](/images/2014/5433_A_4_3_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2014/5425_B_8_8_rna_selected_60x60.jpg) | Group enriched |
NOS3 | Nitric oxide synthase 3 (endothelial cell) | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | ![](/images_static/na_center.gif) | | ![](/images/2168/5988_B_9_2_rna_selected_60x60.jpg) | Tissue enriched |
NOXO1 | NADPH oxidase organizer 1 | FDA approved drug targets Predicted intracellular proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/71540/154564_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
NPC1L1 | NPC1-like 1 | FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/70127/151478_B_8_6_rna_selected_60x60.jpg) | Group enriched |
NPR1 | Natriuretic peptide receptor 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| ![](/images/31087/ihc_selected_60x60.jpg) | ![](/images/31087/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/31087/71781_B_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
NPR2 | Natriuretic peptide receptor 2 | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| ![](/images/11977/ihc_selected_60x60.jpg) | ![](/images/11977/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/11977/28490_B_7_3_rna_selected_60x60.jpg) | Mixed |
NR3C1 | Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Transcription factors
| | | | ![](/images/4248/13405_B_8_2_rna_selected_60x60.jpg) | Expressed in all |
NR3C2 | Nuclear receptor subfamily 3, group C, member 2 | Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/9155/31355_B_9_2_rna_selected_60x60.jpg) | Expressed in all |
NTRK1 | Neurotrophic tyrosine kinase, receptor, type 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| ![](/images/35799/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/35799/129188_B_9_1_rna_selected_60x60.jpg) | Tissue enriched |
OPRD1 | Opioid receptor, delta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images/13744/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images/13744/ihc_cell_selected_60x60.jpg) | ![](/images/13744/30358_B_5_7_rna_selected_60x60.jpg) | Not detected |
OPRK1 | Opioid receptor, kappa 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images/22595/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/22595/50257_B_9_2_rna_selected_60x60.jpg) | Tissue enhanced |